title: [The role of the progesterone antagonist, RU 486 (mifepristone), in preoperative cervical dilatation during the luteal phase. A randomized double-blind study].
authors.forename: H
authors.initials: H
authors.lastname: Fernandez
authors.forename: F
authors.initials: F
authors.lastname: Durlot
authors.forename: C
authors.initials: C
authors.lastname: Dubois
authors.forename: A
authors.initials: A
authors.lastname: Ulmann
authors.forename: R
authors.initials: R
authors.lastname: Frydman
mesh_terms: D001695:Biology; D002584:Cervix Uteri; D019049:Developed Countries; D003933:Diagnosis; D004311:Double-Blind Method; D004703:Endocrine System; D004724:Endoscopy; D005060:Europe; D005602:France; D005835:Genitalia; D005836:Genitalia, Female; D006727:Hormone Antagonists; D006728:Hormones; D015907:Hysteroscopy; D007747:Labor Stage, First; D015735:Mifepristone; D010808:Physical Examination; D010827:Physiology; D012106:Research; D013812:Therapeutics; D014566:Urogenital System; D014599:Uterus
chemical_list: D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone
keywords: Biology; Cervical Dilatation; Cervical Effects; Cervix; Developed Countries; Double-blind Studies; Endocrine System; Endoscopy; Europe; Examinations And Diagnoses; France; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Hysteroscopy; Mediterranean Countries; Physical Examinations And Diagnoses; Physiology; Research Methodology; Ru-486--administraction and dosage; Studies; Treatment; Urogenital System; Uterus; Western Europe